Vitamin B12: When to Order This Test

What Vitamin B12 Measures and Why It Matters

Serum vitamin B12 (cobalamin) quantifies the total circulating cobalamin bound to transport proteins haptocorrin and transcobalamin. This test serves as the first-line screen for cobalamin status, a nutrient required for DNA synthesis, red blood cell maturation, and myelin maintenance throughout the nervous system.

B12 deficiency affects an estimated 6% of adults under age 60 and up to 20% of those over age 60 in the United States, according to data from the National Health and Nutrition Examination Survey 1. Left untreated, deficiency produces hematologic and neuropsychiatric damage that can become irreversible. The American Academy of Family Physicians (AAFP) notes that neurologic symptoms may occur even before anemia develops, making early detection critical 2.

The test itself is straightforward. It requires a standard venous blood draw with no fasting. Results typically return within 24 to 48 hours. However, interpretation demands clinical context because serum B12 alone has limited sensitivity in the 200 to 300 pg/mL range, where roughly 30% of patients are functionally deficient despite seemingly "normal" numbers 3.

Clinical Indications: Who Needs a B12 Test

The primary indications for ordering serum B12 fall into three categories: symptomatic presentation, high-risk medication use, and dietary or absorptive risk factors. Testing should never be delayed when neurologic symptoms are present.

Symptomatic triggers include unexplained macrocytic anemia (MCV >100 fL), peripheral neuropathy presenting as numbness or paresthesias in a stocking-glove distribution, glossitis, and cognitive decline or mood changes without clear etiology. The British Society for Haematology guideline states: "All patients with unexplained neuropsychiatric symptoms should have serum cobalamin measured, regardless of blood count findings" 4.

Medication-related risk centers on metformin. The Diabetes Prevention Program Outcomes Study (DPPOS) demonstrated that long-term metformin use at 850 mg twice daily was associated with a higher risk of biochemical B12 deficiency, with 4.3% of metformin-treated participants developing B12 levels below 203 pg/mL over a median follow-up of 5 years compared to 2.3% on placebo 5. The American Diabetes Association (ADA) Standards of Care recommend periodic B12 monitoring in patients on long-term metformin, particularly those with anemia or neuropathy 6.

Dietary and absorptive risk factors include strict vegan or vegetarian diets (plant foods contain no bioavailable B12), prior bariatric surgery (especially gastric bypass), inflammatory bowel disease affecting the terminal ileum, chronic atrophic gastritis, and age over 65 years. Proton pump inhibitor (PPI) use beyond 2 years also raises concern, though evidence is weaker than for metformin 7.

Normal Vitamin B12 Range and How to Interpret Results

A serum B12 level between 200 and 900 pg/mL (148 to 664 pmol/L) is considered normal by most reference laboratories. Results fall into three interpretive zones, each requiring different clinical responses.

Below 200 pg/mL: This confirms deficiency. No further confirmatory testing is needed. Begin treatment and investigate the underlying cause. A complete blood count, reticulocyte count, peripheral smear, and anti-intrinsic factor antibodies should accompany the workup to evaluate for pernicious anemia.

200 to 300 pg/mL (the gray zone): Serum B12 alone cannot reliably distinguish sufficiency from early deficiency in this range. Order serum methylmalonic acid (MMA). An elevated MMA (above 0.4 micromol/L) in the setting of normal renal function confirms tissue-level B12 deficiency 8. Homocysteine can also be elevated but is less specific because folate deficiency, renal impairment, and hypothyroidism all raise homocysteine independently.

Above 900 pg/mL without supplementation: Unexplained elevation warrants investigation. High B12 in the absence of supplementation has been associated with myeloproliferative disorders, hepatocellular carcinoma, and advanced liver disease 9. A 2012 cohort study published in the Journal of the National Cancer Institute found that individuals with plasma B12 above 600 pmol/L had significantly increased cancer incidence within one year of measurement, suggesting elevated B12 can be a marker of occult malignancy 10.

What a Low Vitamin B12 Means

Low serum B12 signals either inadequate intake, impaired absorption, or both. The clinical consequences span two organ systems: hematologic and neurologic. Both can occur independently, and neurologic damage may precede any blood count abnormality.

Hematologic manifestations include megaloblastic anemia with macro-ovalocytes and hypersegmented neutrophils on peripheral smear, pancytopenia in severe cases, and elevated lactate dehydrogenase from ineffective erythropoiesis. These changes are reversible with treatment.

Neurologic damage is the greater concern. Subacute combined degeneration of the spinal cord, presenting as bilateral dorsal column and corticospinal tract dysfunction, represents the classic severe presentation. More commonly, patients report symmetric paresthesias, impaired proprioception, gait instability, and cognitive slowing. A systematic review of 43 studies found that neurologic symptoms were present in up to 75% of patients with confirmed B12 deficiency, and that delayed treatment beyond 6 months correlated with incomplete neurologic recovery 11.

The most common causes of low B12 differ by age group. In younger adults, dietary insufficiency (veganism) and autoimmune conditions (pernicious anemia) predominate. In older adults, food-cobalamin malabsorption from atrophic gastritis is the leading cause, estimated to affect 10 to 30% of individuals over 60 12.

What a High Vitamin B12 Means

Elevated B12 is frequently iatrogenic, driven by supplementation or B12-containing injections. This is benign and requires no workup. The clinical question arises when B12 is elevated without supplementation.

Non-supplementation causes of high B12 include hepatic release of stored cobalamin during hepatocellular injury, increased production of haptocorrin by granulocytes in myeloproliferative neoplasms such as chronic myelogenous leukemia and polycythemia vera, and renal failure reducing cobalamin clearance. A French cohort study of 3,702 patients found that unexplained B12 above 1,000 pg/mL was associated with solid organ cancers (particularly hepatocellular and metastatic liver disease) with hazard ratios between 1.5 and 2.1 depending on cancer type 9.

The clinical response to elevated B12 should be proportionate. If the patient is on supplements, simply note the expected elevation. If they are not supplementing, check a comprehensive metabolic panel to evaluate liver and renal function, a complete blood count with differential to screen for myeloproliferative features, and consider age-appropriate cancer screening if no clear explanation emerges.

There is no established protocol for "lowering" B12 levels because the elevation itself is not harmful. Treatment targets the underlying cause.

How to Raise Vitamin B12: Treatment of Deficiency

Treatment depends on the cause and severity of deficiency. For patients with neurologic symptoms or severely low levels (below 150 pg/mL), intramuscular cyanocobalamin 1 to 000 mcg daily for 7 days, then weekly for 4 weeks, then monthly indefinitely is the standard approach recommended by the British Society for Haematology 4.

For patients with mild to moderate deficiency without neurologic involvement, high-dose oral supplementation is effective. A randomized controlled trial published in the British Journal of Clinical Pharmacology demonstrated that oral cyanocobalamin 1 to 000 mcg daily was as effective as intramuscular injection for correcting B12 levels and improving hematologic parameters over 90 days 13. This route works even in patients with pernicious anemia because approximately 1% of oral B12 is absorbed by passive diffusion independent of intrinsic factor.

Dr. Ralph Green, professor of pathology and laboratory medicine at UC Davis, has stated: "The evidence now supports oral replacement as a viable first-line option for most patients with B12 deficiency, provided neurologic symptoms are absent and adherence can be assured" 14.

Dietary strategies alone are insufficient to correct established deficiency but play a role in prevention. Foods highest in B12 include clams (84 mcg per 3-ounce serving), beef liver (70 mcg per 3-ounce serving), fortified nutritional yeast, and fortified cereals. The recommended dietary allowance for adults is 2.4 mcg per day 15.

Recheck serum B12 and MMA at 2 to 3 months after starting treatment. Reticulocyte count should peak at 5 to 7 days if megaloblastic anemia was present. Hematologic parameters normalize within 6 to 8 weeks. Neurologic improvement is slower and may take 6 to 12 months, with some deficits persisting permanently if treatment was delayed.

Metformin, PPIs, and Other Drug-Induced B12 Depletion

Metformin reduces B12 absorption by interfering with the calcium-dependent uptake of the B12-intrinsic factor complex at the terminal ileum. The mechanism is well established and dose-dependent. A meta-analysis of 29 studies (N=8,089) confirmed that metformin use reduced serum B12 by an average of 57 pg/mL and increased the odds of deficiency (OR 2.45 to 95% CI 1.74 to 3.44) 16.

The ADA 2024 Standards of Care recommend that clinicians "consider periodic measurement of vitamin B12 levels in metformin-treated patients, especially in those with anemia or peripheral neuropathy" 6. Practical implementation: check B12 at baseline, then annually in patients on metformin doses of 1 to 500 mg per day or higher, or at any time if symptoms arise.

Proton pump inhibitors suppress gastric acid, which is needed to cleave B12 from food proteins. A large case-control study (N=25,956 cases) found PPI use for 2 or more years was associated with a 65% increase in B12 deficiency diagnosis (OR 1.65 to 95% CI 1.58 to 1.73) 7. H2 receptor antagonists showed a similar but weaker association.

Other drugs associated with B12 depletion include colchicine, cholestyramine, and nitrous oxide (which irreversibly oxidizes the cobalt center of B12, causing acute functional deficiency even with normal serum levels). Nitrous oxide exposure in surgical or recreational settings can precipitate acute neurologic deterioration in patients with borderline B12 stores.

Confirmatory Testing: MMA, Homocysteine, and Holotranscobalamin

Serum B12 is a screening test, not a definitive measure of tissue B12 status. When results fall in the gray zone (200 to 300 pg/mL) or when clinical suspicion remains high despite a normal serum B12, functional biomarkers add diagnostic precision.

Methylmalonic acid (MMA) is the most specific confirmatory marker. B12 is a cofactor for the enzyme methylmalonyl-CoA mutase. When intracellular B12 is insufficient, MMA accumulates. An elevated serum MMA (above 0.4 micromol/L) in a patient with normal renal function has a sensitivity of approximately 86% and specificity of 73% for B12 deficiency 8. Renal impairment raises MMA independently and must be accounted for.

Homocysteine rises in both B12 and folate deficiency, making it less specific. It is useful when both deficiencies are being evaluated simultaneously. Normal homocysteine with normal MMA effectively excludes B12 deficiency regardless of the serum B12 level.

Holotranscobalamin (holoTC) measures the biologically active fraction of circulating B12 (bound to transcobalamin II). It may detect deficiency earlier than total serum B12, but it is not widely available and lacks standardization across assays. The British Society for Haematology suggests holoTC as a supplementary test rather than a replacement for serum B12 4.

Special Populations: Pregnancy, Older Adults, and Post-Bariatric Surgery

Certain groups require proactive B12 monitoring rather than symptom-triggered testing.

Pregnancy: B12 requirements increase to 2.6 mcg per day. Maternal deficiency is associated with neural tube defects, intrauterine growth restriction, and preeclampsia. A meta-analysis of 18 observational studies found that low maternal B12 was associated with a 2.0 to 3.0 fold increased risk of neural tube defects 17. The American College of Obstetricians and Gynecologists (ACOG) recommends screening for B12 deficiency in pregnant women who are vegan, have a history of bariatric surgery, or present with macrocytic anemia 18.

Older adults (age 65 and above): Atrophic gastritis affects an estimated 20 to 50% of this population, reducing the ability to cleave B12 from food proteins. The Institute of Medicine recommends that adults over 50 obtain most B12 from fortified foods or supplements because crystalline B12 does not require acid-pepsin digestion 15.

Post-bariatric surgery: Roux-en-Y gastric bypass and biliopancreatic diversion bypass the sites of intrinsic factor secretion and B12 absorption. Deficiency rates range from 20 to 35% within 2 to 5 years postoperatively. The American Association of Clinical Endocrinology (AACE) 2019 bariatric guidelines recommend lifelong B12 monitoring and prophylactic supplementation (1 to 000 mcg oral daily or monthly injections) starting immediately after surgery 19.

Patients on chronic hemodialysis lose water-soluble vitamins during treatment and should have B12 checked at least annually as part of nutritional surveillance.